Which Client Is Suspected To Have An Increased Risk Of Hyperlipidemia? Select All That Apply.

Standing Education Activity

Hyperlipidemia is a term that encompasses diverse genetic and acquired disorders that depict elevated lipid levels within the body. Information technology is a very common disorder, especially in the Western hemisphere, merely also throughout the globe. Hyperlipidemia itself does not typically lead to critical symptoms itself, withal, having this underlying pathology will ofttimes atomic number 82 to serious illnesses that may ultimately lead to expiry. To lower morbidity and bloodshed rates associated with this disorder, information technology is critical to constitute an early on diagnosis and prevent the progression of the disease. This activeness reviews the etiology, pathophysiology, evaluation, and treatment guidelines associated with hyperlipidemia. It also highlights the role of interprofessional communication and teamwork when managing the diagnosis and the right treatment of patients diagnosed with hyperlipidemia.

Objectives:

Describe the pathophysiology of hyperlipidemia.
Review the steps in the evaluation of hyperlipidemia.
Outline the management options bachelor for hyperlipidemia.
Explicate the importance of early diagnosis and treatment of hyperlipidemia.

Access free multiple choice questions on this topic.

Introduction

Hyperlipidemia is a condition that incorporates various genetic and caused disorders that describe elevated lipid levels inside the human body. Hyperlipidemia is extremely common, especially in the Western hemisphere, simply also throughout the earth. Alternatively, a more objective definition describes hyperlipidemia as low-density lipoprotein (LDL), total cholesterol, triglyceride levels, or lipoprotein levels greater than the 90th percentile in comparing to the general population, or an HDL level less than the 10th percentile when compared to the general population.[1] Lipids typically include cholesterol levels, lipoproteins, chylomicrons, VLDL, LDL, apolipoproteins, and HDL.[ii]

Through a vast array of trials and studies, it has been consistently shown that elevated levels of LDL cholesterol increase a person'due south take chances for the evolution of atherosclerotic plaques and subsequent vascular disease. In stark contrast, loftier-density lipoprotein (HDL) cholesterol assists in regulating cholesterol levels to foreclose imbalances that would increase the chance of atherosclerotic vascular disease. Each patient's LDL cholesterol goal is conditional on their overall cardiovascular risk, and medical therapy should be independently tailored to the patient. Managing take a chance factors, such equally hyperlipidemia, to diminish the chance for atherosclerotic cardiovascular illness is referred to as "primary prevention." The grounds for lowering LDL cholesterol derives from widespread epidemiologic information that reveals a positive, continuous correlation between LDL cholesterol levels, cardiovascular events, and patient bloodshed.[1]

Handling of hyperlipidemia continues to evolve as we better anticipate the underlying pathophysiology, and we concurrently better on preceding medical therapies. This commodity will overview the groundwork, diagnosis, and nigh contempo treatment guidelines for hyperlipidemia.

Etiology

Hyperlipidemia subdivides into two wide classifications: primary (familial) or secondary (acquired) hyperlipidemia. Principal hyperlipidemia derives from a plethora of genetic disorders that a patient may inherit through birth, while secondary hyperlipidemia typically originates from an alternating underlying etiology, such as an unhealthy diet, medications (amiodarone, glucocorticoids), hypothyroidism, uncontrolled diabetes, and/or a poor lifestyle regimen.[2]

Underlying disturbances in lipoprotein metabolism are often familial, making a patient's family history that much more valuable. For example, near 54 percent of patients (in 1 written report) with a history of premature coronary artery disease had an underlying hereditary disorder. In about patients, hyperlipidemia has a polygenic inheritance blueprint, and manifestations of the disorder are largely influenced by secondary factors such as (key) obesity, saturated fatty intake, and the cholesterol content within a person'south diet.[1] Various less conventional take chances factors will also announced below.

Cholesterol is the circulating fatty substance, most implicated in the atherogenic procedure. Its origin is twofold: 300 to 700 mg per day is of exogenous origin, that is, coming from an excessive intake of dietary fats, peculiarly of brute origin; 800 to 1200 mg per mean solar day is the work of an endogenous synthesis, in detail the liver. In add-on to excessive consumption of fauna fats, other frequent causes of hypercholesterolemia and/or increment in triglycerides are diabetes, chronic renal failure, nephrotic syndrome, hypothyroidism, age, sedentary lifestyle. Other iatrogenic causes may exist the intake of certain drugs such as thiazide diuretics, beta-blockers, estrogen-progestin contraceptives, antiretrovirals.

Genetic dyslipidaemias, much rarer, are the basis of the changes in the blood lipid rate in the measure of about threescore% and are frequently responsible for cardiovascular diseases at an early age.

Epidemiology

There are over three 1000000 adults throughout the Usa and Europe that currently have a diagnosis of hyperlipidemia, and that number continues to ascent at a drastic pace. Hyperlipidemia is typically a chronic, progressive disease process that demands lifestyle and dietary changes, with the potential need for boosted lipid-lowering medications. The degree of hyperlipidemia is highest in patients with premature coronary artery illness (CAD), defined as CAD arising in males before age 55 to 60 years and females before age 65 years. Under the prior specified circumstances, the incidence of hyperlipidemia is around 75-85%, opposed to roughly twoscore to 48% in the control population of comparable historic period, merely without the presence of premature coronary artery disease.[1]

Estimates are that over 50% of American adults accept elevated LDL levels, and it is speculated that under 35% of those patients adequately manage their high LDL levels, clearly depicting an undertreated disease. Per the JAMA Network, "Prevalence of dyslipidemia was significantly greater among whites than blacks (women, 64.7% vs. 49.five%; and men, 78.4% vs. 56.7%;P<.001 for both) and amid men than women (P≤.02 in every ethnic group)."[two] Intuitively, in countries with lower overall rates of obesity and saturated fat consumption, the prevalence of hyperlipidemia and subsequent coronary artery disease is lower, when assorted to rates in Europe and throughout the United States.

Children nether two years of age, if underweight or obese, may develop secondary (not-genetic) pediatric hyperlipidemia.

Pathophysiology

Hyperlipidemia, in item elevated LDL (hypercholesterolemia), is one of the most prevalent risk factors contributing to the evolution of atherosclerosis and consequent vascular disease. It is simply defined as elevated concentrations of lipids or fats within the blood. Numerous factors contribute to the development of atherosclerosis, including endothelial damage, hyperlipidemia, inflammatory and immunologic factors, plaque erosion or rupture, hypertension, and smoking. Atherosclerosis frequently remains asymptomatic until plaque stenosis reaches seventy to fourscore% of the vessel's diameter. Atherosclerosis originates subsequently underlying endothelial damage occurs, which appears to stem from the loss of nitric oxide within the endothelium. This procedure leads to increased inflammation direct around the site of dysfunction, permitting the accumulation of lipids inside the innermost layer of the endothelial wall. The lipids are and then engulfed past macrophages, leading to the establishment of "foam cells." This cholesterol build-up inside the "foam cells" causes subsequent mitochondrial dysfunction, apoptosis, and, ultimately, necrosis of the underlying tissues. Smooth muscle cells encapsulate the pack of "foam cells" or debris, which produces a fibrotic plaque that inhibits the underlying lipids (debris) from being destroyed[i]

Tissue factor, alongside increased platelet activity, is known equally a primary initiator of coagulation, which increases the take chances for plaque rupture and thrombosis. Atherosclerotic plaques evolve via 2 distinct mechanisms: a slower, chronic plaque build-upwards that progressively leads to luminal stenosis, versus an acute onset of rapid luminal obstruction secondary to plaque rupture and thrombosis[3] Both mechanisms are capable of causing clinically meaning illness that should be addressed by a md as soon as possible.

For about patients, hyperlipidemia is polygenic in inheritance, and the manifestation of the disorder is considerably influenced by factors such as (primal) obesity, saturated fat intake, and the cholesterol content within a person's diet. Some other mechanism involves elevated levels of "apo B-100" lipoproteins within the plasma, which may lead to atherosclerotic illness, even when the patient has no other risk factors. Information technology is often that there is a combination of genetic and ecology factors at play that ultimately contribute to a person's chance of developing hyperlipidemia and cardiovascular illness.

Many systemic diseases, which stimulate an inflammatory sub-layer with clinical or sub-clinical values, can cause dyslipidemia and atherosclerotic problems. Some examples:

Psoriasis
Crohn disease
Inflammatory bowel disease
Chronic obstructive pulmonary illness
Depression
Chronic pain
Pediatric alopecia areata
Chronic kidney disease

Histopathology

In the presence of hyperlipidemia, not simply the vascular structures are negatively involved but also other tissues. Fort example, enquiry has demonstrated through patellar tendon shear wave velocities that there is a direct relationship between the intrinsic alteration of the patellar tendon and the presence of hyperlipidemia. The tendon becomes stiffer with morphological alteration of the tissue and changes in the blazon of cells nowadays. Increases the number of macrophages in the tendon tissue, damaged collagen fibers, replacement of collagen cells with lipid cells; collagen type III increases, which is less elastic, matrix metalloproteinases increase. The tendon in the presence of hyperlipidemia becomes mechanically less effective and more prone to injury.

History and Physical

Regularly, patients presenting with underlying hyperlipidemia remain asymptomatic, therefore obtaining a precise and thorough history is essential. Upon taking a patients history, it is crucial to obtain a profound agreement of each patient'south family history of cardiovascular disease, hyperlipidemia, and/or familial hypercholesterolemia; their diet and exercise habits; tobacco, alcohol, or drug utilise; the presence of coronary avenue affliction; hazard factors or history of CAD; and/or symptoms of peripheral arterial disease or angina[four]

In addition to obtaining a detailed history, a focused physical exam is also very important. Obtaining accurate claret pressure level measurements, observing the patients skin for xanthomas, listening for carotid and femoral bruits for evidence of stenosis, listening for an S4 eye sound, and palpating for intact peripheral pulses in all four extremities are fast and unproblematic concrete exam findings that can assist in your diagnosis of hyperlipidemia[1]

Evaluation

Diverse experts have developed lipid screening guidelines that include the "lipid contour" to measure cholesterol and triglyceride levels. Guidelines differ equally to what historic period principal providers should start screening and how often they should screen patients for hyperlipidemia. In general, it is brash that routine lipid screening should occur when a male turns 35 years of age (if no other cardiovascular gamble factors) or 25 years of historic period (if the patient has other cardiovascular chance factors). It is also suggested that routine lipid screening exist initiated in females at 45 years of age (if no other cardiovascular risk factors present) or 30 to 35 years of age (if the patient has other cardiovascular risk factors)[i] For lower-risk patients, lipid screening every five years is reasonable, and more frequent screening is recommended as the patient's cardiovascular risk increases.

As stated above, the nigh valuable laboratory test to collect is checking fasting lipid profile, which routinely includes LDL, HDL, triglycerides, and total cholesterol. A v-LDL, total cholesterol: HDL, and LDL: HDL ratios can be added on for a more than comprehensive test. It is necessary to not eat or drink anything besides water for 9 to 12 hours as not to skew the results of the lipid panel (mainly the triglyceride levels).[4]

Earlier starting a statin for high LDL levels, information technology is of import to obtain liver part tests to ensure there is no prior liver dysfunction, as statins may exacerbate this issue. For risk stratification purposes, a Hgb A1c level is necessary to screen for diabetes mellitus, and the clinician should e'er examine blood pressure measurements to ensure the patient does not accept underlying hypertension. Additionally, a TSH should be ordered to rule out underlying thyroid abnormalities, and a simple urinalysis can exist collected to screen for albuminuria. These tests are disquisitional for take chances-stratification of your patient to accurately appraise the potential risks versus benefits of initiating medical therapy in a patient with hyperlipidemia.

Treatment / Direction

The decision to treat elevated LDL cholesterol levels depends on the determination of overall cardiovascular hazard by the patient'southward principal medico, and this should be discussed in groovy detail with the patient. The absolute adventure reduction affiliated with lipid-lowering therapy for hyperlipidemia is more often than not less than for patients with known underlying cardiovascular disease. To reduce risk in patients without a known diagnosis of cardiovascular disease, only treatments of elevated LDL cholesterol take proven to be of clinical benefit. In that location is no proven clinical benefit to the treatment of hypertriglyceridemia or low HDL cholesterol levels.[five]

Initial treatment modalities are focused on diet and lifestyle modification, with the possible add-on of lipid-lowering medications if needed. Patients with mild hyperlipidemia and low ASCVD take chances (beneath 7.5% ten-year adventure) should focus on a low fat, depression sugar diet, and moderate to loftier-intensity concrete activity (recommended thirty minutes per twenty-four hours, 5 to 6 days per week). The AHA advises limiting saturated fat consumption to about 5% of your daily calories and restricting the total quantity of trans-saturated fat consumption as much as possible. Quitting smoking, lowering blood pressure, and losing weight have all proven to be very advantageous in regards to lowering vascular disease take a chance. For patients at moderate to high ASCVD take chances (over 7.5% 10-yr risk), the add-on of lipid-lowering "statin" medications should exist added.[6]

The virtually well rounded and complete meta-analysis investigating primary prevention trials in hyperlipidemia patients discovered an all-crusade bloodshed do good and that lowering LDL cholesterol is effective at decreasing cardiovascular events, in particular, reducing the risk of myocardial infarction. At that place is a clear and proven benefit to statin therapy for the vast majority of patients, from low risk to high risk, and if side effects and financial constraints did not exist, most all patients would exist prescribed statin therapy. Therefore, these medication's side effects and costs should be weighed confronting the individual patient's potential benefit from taking the drug.

Fundamental Recommendations for Practice: SORT evidence rating system [7]:

Patients with a high hazard of ASCVD (>7.5% 10-yr chance) should receive statin therapy for primary prevention: Rating B.
Statin therapy should exist initiated for secondary prevention in patients with known ASCVD, absent whatsoever contraindication: Rating A
Niacin, fibrates, and omega-3 fatty acids should not be routinely given for chief or secondary prevention of ASCVD: Rating A
A moderate-intensity statin plus ezetimibe should merit consideration as an alternative in patients with acute coronary syndrome who cannot tolerate loftier-intensity statin therapy: Rating B.
Moderate-intensity statins include: lovastatin 40 mg, pravastatin 40 mg, simvastatin xl mg, atorvastatin 10 to xx mg, and rosuvastatin 5 to 10 mg
Loftier-intensity statins include: atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg

If the provider and patient reach a common decision to initiate medical therapy with statins, the overall take chances reduction in cardiovascular events is customarily effectually 20 to thirty% in near clinical trials. The commonly referred to trials of which the majority of guidelines are based, included pravastatin forty mg, lovastatin 20 to 40 mg, atorvastatin ten mg, and rosuvastatin 10 mg, so general recommendations are to choose one of these statins listed.[5] Information technology is ever of import to schedule close follow upwards with patients that are starting lipid-lowering statin therapy. The vast majority of benefits arising from statin therapy originates from the moderate dose, with a much more atomic benefit deriving from the improver of loftier-intensity therapy. Yet, the benefit of high-intensity therapy remains clinically significant and should merit consideration for all loftier-risk patients.

If a patient encounters an allergy or intolerance to a statin medication, the suggestion is to reduce the original or to transition to a unlike lipid-lowering medication altogether. Among patients that accept reported muscle-related statin intolerances, co-ordinate to ane 24 week trial, evolocumab (PCSK9 inhibitor) reduced LDL cholesterol levels significantly more when compared to ezetimibe.[8] All the same, both of these medications are reasonable secondary options for treatment.

Differential Diagnosis

It is imperative for diagnosing providers to assemble a comprehensive list of differentials when screening a patient for hyperlipidemia. Primary disorders should e'er be considerations; these include familial hypercholesterolemia, familial combined hyperlipidemia, dysbetalipoproteinemia, familial defective apo B-100, and PCSK9 gain of role mutations.

And then, these secondary illness processes must also be in the differential when diagnosing a patient with hyperlipidemia: obstructive liver disease or biliary obstruction, hypothyroidism, nephrotic syndrome, chronic renal insufficiency, anorexia, obesity, metabolic syndrome, and diabetes.[4] A full history and concrete complete with comprehensive labs should be obtained to narrow down the differential and make the correct diagnosis.

Prognosis

Hyperlipidemia is frequently a life-long illness process, but one that is typically quite manageable. However, if hyperlipidemia is left untreated, the disease is progressive and volition often lead to astringent underlying vascular disease processes, which can bear witness fatal. Ongoing persistent exposure to high serum lipid levels throughout early adulthood increases the person's subsequent chance of coronary heart disease in a dose-dependent fashion.[ix]

Adults with ongoing exposure to moderate or severe elevations in non-HDL cholesterol levels have concurrent elevated risks for developing coronary middle affliction and would likely do good from aggressive medical handling modalities, including, which includes loftier-intensity statin therapy in addition to diet and lifestyle modifications. Based on a xx twelvemonth follow up of the "West of Scotland Coronary Prevention Report," the researchers noted that patients who received statin therapy for five years had improved survival rates and a clinically significant reduction in cardiovascular disease over the 20 years. This information supports the numerous other studies and trials that also reveal a significant cardiovascular risk reduction when using statin therapy accordingly, and there was the implementation of a proactive handling approach.[ten]

Complications

Complications from undertreated or untreated hyperlipidemia include all types of vascular affliction, which may prove fatal downwards the road. These include, merely are not limited to, coronary artery disease, peripheral artery illness, cerebrovascular accidents, aneurysms, blazon 2 diabetes, high blood pressure, and fifty-fifty death.[10]

Statin medication complications include myopathy, renal injury, arthralgia, extremity pains, nausea, myalgia, elevated liver enzymes/hepatotoxicity, diarrhea, and rhabdomyolysis. Reportedly up to 5 to 20% of patients taking a statin medication experience a muscle-related intolerance.[viii] A lower dose of the statin should be attempted and/or attempting to transition to some other lipid-lowering medication such as ezetimibe or evolocumab.

Postoperative and Rehabilitation Intendance

Aerobic exercise has shown to increment the levels of the HDL-cholesterol poly peptide, with an anti-atherogenic activeness: the HDL that transports cholesterol from the walls of the arteries and peripheral tissues to the liver and the same HDL has an antioxidant and anti-inflammatory capacity that induces the release of nitric oxide (vasodilator compound). Estimates are that adding 10 minutes of physical action to daily practice increases the concentration of HDL by 1.four mg/dl, and it has been calculated that, on average, an adequate grooming program can increase cholesterol HDL of 4.half dozen%.[xi]

A combination of aerobic and anaerobic activity is equally capable of positively influencing blood lipid levels.[12]

I hour per calendar week of resistance preparation (anaerobic activity) tin can improve the lipid profile and corresponds to a right indication in order not to exceed in physical effort and maintain optimal wellness.[13]

Deterrence and Patient Education

All patients diagnosed with hyperlipidemia must empathize how the affliction affects their organs and the health risks that it may pose. A proper diet, smoking abeyance, and lifestyle modifications should always exist discussed. If pharmacological therapy is necessary, give-and-take of the risks and benefits of each medication should be explored before initiation. The primary care physician and pharmacist alike have a duty to educate the patient on medication compliance, side effects, interactions, and the overall risks versus benefits of the medications prescribed. The patient must also understand the potential risks related to not taking the medication and what alternatives they may have as handling options.

Enhancing Healthcare Team Outcomes

The diagnosis of hyperlipidemia tin can be a difficult one, often in the sense that there are no presenting symptoms. To establish a diagnosis, the primary intendance doctor or attention medico ordering lab piece of work must have a high suspicion for the affliction or be completing routine screening labs. Typically the physician needs collaboration with nurses (obtain vital signs, request history, etc.) who are also critical in the overall process of adept patient care. Once the diagnosis is made, interprofessional communication and teamwork are vital to ensure the patient receives proper handling based on the about upwards to date treatment guidelines.

Following diagnosis, the primary intendance physician typically volition manage the disorder with diet, exercise, and/or medications. This diagnosis and treatment plan must be communicated to the patient'southward other physicians for optimal care. It also involves communication with the patient about medication side furnishings from the prescribing md and also from the pharmacist if needed. The pharmacist is too able to re-explicate any potential adverse effects or interactions from the medications prescribed by the physician.

If diet education is needed, often, the patient can consult with a nutritionist or dietitian.

Proper interprofessional communication between these specialties and subspecialties and with the patient will ensure right treatment and medication adherence, keeping the patient safe, and ideally preventing the progression of the disease. The patient should exist monitored yearly or more often at the discretion of his or her chief care physician to keep close tabs on the progression of the disease.

Review Questions

Figure

The effigy shows the inside of an arterial vessel and the germination of atherosclerotic plaques due to the presence of hyperlipidemia. Contributed by Bruno Bordoni, PhD.

References

1.: Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med. 1971 Sep;75(3):471-2. [PubMed: 5568160]
2.: Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ, Frost PH, Haffner SM. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab. 2000 Jun;85(6):2089-112. [PubMed: 10852435]
3.: Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J., American Center Association. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation. 2004 Jun 01;109(21):2617-25. [PubMed: 15173044]
4.: Vodnala D, Rubenfire Yard, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012 Sep fifteen;110(6):823-5. [PubMed: 22658245]
5.: Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart affliction continuous and graded? Findings in 356,222 master screenees of the Multiple Hazard Gene Intervention Trial (MRFIT). JAMA. 1986 Nov 28;256(20):2823-8. [PubMed: 3773199]
6.: The Lipid Research Clinics Coronary Chief Prevention Trial results. 2. The relationship of reduction in incidence of coronary center disease to cholesterol lowering. JAMA. 1984 January 20;251(3):365-74. [PubMed: 6361300]
7.: Catapano AL, Graham I, De Capitalist G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi K, Taskinen MR, Tokgozoglu Fifty, Verschuren WMM, Vlachopoulos C, Woods DA, Zamorano JL, Cooney MT., ESC Scientific Document Group. 2022 ESC/EAS Guidelines for the Direction of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999-3058. [PubMed: 27567407]
8.: Nissen SE, Stroes Eastward, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar Due north, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA., GAUSS-iii Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-three Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580-90. [PubMed: 27039291]
9.: Vallejo-Vaz AJ, Robertson Chiliad, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (Due west of Scotland Coronary Prevention Written report) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Circulation. 2017 Nov 14;136(20):1878-1891. [PubMed: 28877913]
x.: Ford I, Murray H, McCowan C, Packard CJ. Long-Term Safety and Efficacy of Lowering Depression-Density Lipoprotein Cholesterol With Statin Therapy: 20-Twelvemonth Follow-Upwards of West of Scotland Coronary Prevention Study. Circulation. 2016 Mar fifteen;133(eleven):1073-lxxx. [PMC gratuitous commodity: PMC4894764] [PubMed: 26864092]
eleven.: Franklin BA, Brubaker P, Harber MP, Lavie CJ, Myers J, Kaminsky LA. The Journal of Cardiopulmonary Rehabilitation and Prevention at twoscore yr and Its Office in Promoting Preventive Cardiology: Office two. J Cardiopulm Rehabil Prev. 2020 Jul;xl(4):209-214. [PubMed: 32604250]
12.: Álvarez C, Ramírez-Campillo R, Lucia A, Ramírez-Vélez R, Izquierdo M. Concurrent do training on hyperglycemia and comorbidities associated: Non-responders using clinical cutoff points. Scand J Med Sci Sports. 2019 Jul;29(7):952-967. [PubMed: 30825342]
13.: Bakker EA, Lee DC, Sui X, Eijsvogels TMH, Ortega FB, Lee IM, Lavie CJ, Blair SN. Association of Resistance Exercise With the Incidence of Hypercholesterolemia in Men. Mayo Clin Proc. 2018 Apr;93(4):419-428. [PMC free article: PMC5889308] [PubMed: 29428677]